


Curriculum Vitae

| | | |
|---|--|---|
| Name | Minkyu Jung |  |
| Current Position & Affiliation | Associate Professor Division of Medical Oncology, Department of Internal Medicine, Yonsei cancer center, Yonsei University Healthy System | |
| Country | Rep. of Korea | |

Educational Background

| | |
|-----------|--|
| 1995-1999 | Department of Biology, Yonsei University College of Science, Seoul, Korea |
| 1999-2003 | Yonsei University College of Medicine, Seoul, Korea |
| 2006-2008 | Master of Medical Science, Graduate School Yonsei University College of Medicine, Seoul, Korea |
| 2008-2017 | Doctor of Philosophy, Medical Science, Graduate School Yonsei University College of Medicine, Seoul, Korea |

Professional Experience

| | |
|---------------|--|
| 2003.3-2004.2 | Rotating Internship Yonsei University College of Medicine Severance Hospital, Seoul, Korea |
| 2005.3-2009.2 | Residency in Internal Medicine Yonsei University College of Medicine Severance Hospital, Seoul, Korea |
| 2009.3-2010.2 | Clinical fellow in Medical Oncology Division of Medical Oncology, Department of Internal Medicine Yonsei Cancer Center, Yonsei University College of Medicine Yonsei University Health System, Seoul, Korea |
| 2010.3-2010.9 | Assistant Clinical Research Professor in Medical Oncology Division of Medical Oncology, Department of Internal Medicine Yonsei Cancer Center, Yonsei University College of Medicine Yonsei University Health System, Seoul, Korea |

- 2010.10-2011.2 Clinical Instructors in Medical Oncology
Gachon University Gil hospital, Incheon, Korea
- 2011.3-2012.2 Clinical Assistant Professor in Hematology and Oncology
Gachon University Gil hospital, Incheon, Korea
- 2012.3-2014.2 Clinical Assistant Professor in Medical Oncology
Yonsei cancer center, Yonsei University College of Medicine
Yonsei University Healthy System, Seoul, Korea
- 2014.3-2019.2 Assistant Professor in Medical Oncology
Yonsei cancer center, Yonsei University College of Medicine,
Yonsei University Healthy System, Seoul, Korea
- 2017.9-2019.8 Visiting Scholar in Well Cornell Medicine, New York, USA
- 2019.3-Current Associate Professor in Medical Oncology
Yonsei cancer center, Yonsei University College of Medicine,
Yonsei University Healthy System, Seoul, Korea

Professional Organizations

Korean Association of Internal Medicine
Korean Cancer Association
Korean Cancer Study Group
Korean Society of Medical Oncology
American Society of Clinical Oncology
American Association for Cancer Research
European Society of Medical Oncology

Main Scientific Publications

1. Lee JB, Jung M, Rha SY. et al. Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. *Cancer Res Treat.* 2021 Apr;53(2):323-329
2. Han JW, Jung M, Kim JY et al. Plasma Membrane Localized GCaMP-MS4A12 by Orai1 Co-Expression Shows Thapsigargin- and Ca²⁺-Dependent Fluorescence Increases. *Mol Cells.* 2021 Apr 30;44(4):223-232
3. Jung M, Yang Y, Jin MM, et al. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. *Mol Ther Oncolytics.* 2020 Aug 21;18:587-601
4. Park H, Jung M, Ahn JB, Jeon JY, et al. Objectively measured physical activity during chemotherapy in colon cancer patients. *Support Care Cancer.* 2020 Jun;28(6):2597-2604.

5. Jung M, Rha SY. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. *Gastric Cancer*. 2019 Nov;22(6):1153-1163.
6. Kim MH, Jung M, et al. Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. *Cancer Res Treat*. 2019 Apr;51(2):819-831.
7. Jung M, Ryu MH, Rha SY, Cho JY et al. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). *Gastric Cancer*. 2018 Sep 21(5):819-830
8. Lee CK, Jung M, Rha SY et al. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. *Cancer Res Treat*. 2019 Jan;51(1):1-11
9. HS Kim, M Jung, HN Kang, SM Ali, T-M Kim, BC Cho, et al. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. *Oncogene*. 2017 Jun8;32(23)3334-3345
10. Kim CG, Jung M et al. Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. *BMC Cancer*. 2017 Sep 2;17(1):615.
11. Park JS Cho A. Jung M et al. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. *Gastric Cancer*. 2018 Mar;21(2):213-224
12. Jung M, Lee J, Shin SJ et al. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. *Cancer Res Treat*. 2017 Jan;49(1):44-53.
13. Lim SM, Cho A, Jung M et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. *Ann Nucl Med*. 2016 May;30(4):279-86
14. Jung M, Shin SJ, Ahn JB et al. A Randomized Phase 2 Study of Neoadjuvant Chemoradiation Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. *Int J Radiat Oncol Biol Phys*. 2015 Dec 1;93(5):1015-22.
15. Park HS, Jung M, et al. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. *Ann Surg Oncol*. 2016 Mar;23(3):928-35
16. Lee CK, Jung M, et al. Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. *Ann Surg*. 2016 Jan;263(1):96-102.

17. Park HS, Jung M et al. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. *Ann Surg Oncol*. 2015 Jan;22(1):224-31
 18. Ahn HK, Jung M, Cho EK et al. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. *Tumour Biol*. 2014 Jun;35(6):5735-40
 19. Jung M, Chung HC et al. Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. *Ann Surg Oncol*. 2013 Aug;20(8):2615-24.
 20. Jung M, Cho BC, LEE JH et al. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. *Yonsei Med J*. 2012 Nov 1;53(6):1128-35.
 21. Jung M, Shin SJ et al. Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. *BMC Cancer*. 2012 Oct 12;12:471.
 22. Jung M, Sohn J et al. Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. *PLoS One*. 2012;7(9):e45127
 23. Jung M, Lee CH, Cho BC et al. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. *Exp Ther Med*. 2011 Jul;2(4):685-693.
 24. Jung M, Chung HC et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. *Ann Surg Oncol*. 2010 Dec;17(12):3259-68.
 25. Jung M, Ahn JB, Shin SJ, Rha SY et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome. *J Neurooncol*. 2011 Jan;101(1):49-55.
 26. Jung M, Rha SY et al. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. *J Cancer Res Clin Oncol*. 2010 Apr;136(4):517-26.
-